Nomura Holdings
APLS

Nomura Holdings’s Apellis Pharmaceuticals APLS Stock Holding History

Nomura Holdings’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.41M Sell
59,800
-50,300
-46% -$1.08M 0.01% 876
2025
Q4 		$2.77M Buy
110,100
+6,100
+6% +$143K ﹤0.01% 982
2025
Q3 		$2.35M Buy
+104,000
New +$2.43M ﹤0.01% 1078

Other funds holding APLS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Nomura Holdings's APLS Position: Q1 2026 in Review

Nomura Holdings sold out of Apellis Pharmaceuticals (APLS) in Q1 2026, closing a stake of 14,200 shares — an estimated $306K sold.

Nomura Holdings first reported a position in APLS in Q3 2019 and held it in 16 quarters. The position peaked at $9.56M in Q3 2021. 321 funds tracked by Wall St. Rank hold APLS as of Q1 2026.

  • Nomura Holdings reported no remaining Apellis Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Nomura Holdings sold 14,200 Apellis Pharmaceuticals shares in Q1 2026, an estimated $306K.
  • Nomura Holdings first reported a position in Apellis Pharmaceuticals in Q3 2019 and held it in 16 quarters.
  • Nomura Holdings's Apellis Pharmaceuticals position peaked at $9.56M in Q3 2021.
  • 321 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q1 2026.

Based on Nomura Holdings's 13F filing for Q1 2026, filed 15 May 2026.